e-learning
resources
Milan 2017
Monday, 11.09.2017
Experimental PH
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model
J. Bordenave (Le Kremlin-Bicêtre Cedex, France)
Source:
International Congress 2017 – Experimental PH
Session:
Experimental PH
Session type:
Thematic Poster
Number:
2385
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Bordenave (Le Kremlin-Bicêtre Cedex, France). Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model. 2385
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Specific ligand for the innate repair receptor, ARA290, attenuates pulmonary hypertension in an elastase-induced murine model of emphysema
Source: International Congress 2017 – Experimental PH
Year: 2017
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Year: 2017
Two rat models of hemolysis-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Characterisation of endogenous IL-33 using a model of
Alternaria
-induced pulmonary inflammation
Source: Annual Congress 2012 - Cellular signalling mechanisms in the airways
Year: 2012
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Circulating fibrocyte recruitment and differentiation inhibited by treprostinil in pulmonary hypertension murine model
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Role of NFATc3 in chronic hypoxia induced pulmonary hypertension in neonatal mice
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010
Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 365s
Year: 2005
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Reduction of endogenous acetylcholine contributes to pulmonary inflammation in a model of emphysema in mice
Source: Annual Congress 2012 - The many roads to lung injury
Year: 2012
Reversibility of the monocrotaline pulmonary hypertension rat model
Source: Eur Respir J 2013; 42: 553-556
Year: 2013
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept